Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1IMmotion-151 (PDL1 >1%), 20191JAVELIN Renal 101( PDL1>1%), 2019atezolizumab plus bevacizumab vs. avelumab plus axitinib 1.22 [0.85; 1.74]1.22 [0.85;1.74]atezolizumab plus bevacizumab vs. avelumab plus axitinib 1.22 [0.85; 1.74]atezolizumab plus bevacizumab vs. sunitinib 0.84 [0.62; 1.14]0.84 [0.62;1.14]atezolizumab plus bevacizumab vs. sunitinib 0.84 [0.62; 1.14]avelumab plus axitinib vs. atezolizumab plus bevacizumab 0.82 [0.57; 1.18]0.82 [0.57;1.18]avelumab plus axitinib vs. atezolizumab plus bevacizumab 0.82 [0.57; 1.18]avelumab plus axitinib vs. sunitinib avelumab plus axitinib better 0.69 [0.58; 0.83]0.69 [0.58;0.83]avelumab plus axitinib vs. sunitinib avelumab plus axitinib better 0.69 [0.58; 0.83]sunitinib vs. atezolizumab plus bevacizumab 1.19 [0.87; 1.62]1.19 [0.87;1.62]sunitinib vs. atezolizumab plus bevacizumab 1.19 [0.87; 1.62]sunitinib vs. avelumab plus axitinib avelumab plus axitinib better 1.45 [1.21; 1.74]1.45 [1.21;1.74]sunitinib vs. avelumab plus axitinib avelumab plus axitinib better 1.45 [1.21; 1.74]sunitinibatezolizumab plus bevacizumabavelumab plus axitinibatezolizumab alonedirect evidencenetwork meta-analysis
T vs. C sunitinibatezolizumab plus bevacizumabavelumab plus axitinibatezolizumab alone
sunitinib---1.19
0.87; 1.62		1.45
1.21; 1.74		NA
atezolizumab plus bevacizumab0.84
0.62; 1.14		---1.22
0.85; 1.74		NA
avelumab plus axitinib0.69
0.58; 0.83		0.82
0.57; 1.18		---NA
atezolizumab aloneNANANA---

pathologies: 152 - treatments: 361 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons